• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Fulvestrant-palbociclib and letrozole-palbociclib are equally effective for HR⁺ advanced breast cancer

byTeddy Guo
October 20, 2021
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

Click here to read this study in JAMA Oncology. 

RELATED REPORTS

#VisualAbstract: Elinzanetant Effectively Reduces Vasomotor Symptoms from Endocrine Therapy for Breast Cancer

Imlunestrant extends progression-free survival in ER-positive, HER2-negative breast cancer

Less frequent mammography is non-inferior to annual screening for breast cancer survival in women after curative treatment

Tags: advanced breast cancerBreast Cancerfulvestranthormone receptor-positive breast cancerletrozoleLetrozole (Femara)palbociclibSelective estrogen receptor modulators
Previous Post

Nonnutritive sweeteners elicit more neural response to food cues compared to sugar

Next Post

Adjuvant atezolizumab shows benefit in patients with stage II-IIIA non-small-cell lung cancer

RelatedReports

#VisualAbstract: Elinzanetant Effectively Reduces Vasomotor Symptoms from Endocrine Therapy for Breast Cancer
StudyGraphics

#VisualAbstract: Elinzanetant Effectively Reduces Vasomotor Symptoms from Endocrine Therapy for Breast Cancer

June 17, 2025
One-year of Herceptin preferable to two-year regimen
Oncology

Imlunestrant extends progression-free survival in ER-positive, HER2-negative breast cancer

April 11, 2025
3D mammography (tomosynthesis) enhances accuracy of breast cancer screening
Chronic Disease

Less frequent mammography is non-inferior to annual screening for breast cancer survival in women after curative treatment

April 2, 2025
#VisualAbstract Lack of sentinel-lymph node biopsy does not alter survival in early invasive breast cancer
StudyGraphics

#VisualAbstract Lack of sentinel-lymph node biopsy does not alter survival in early invasive breast cancer

March 27, 2025
Next Post
Lessons from real-world implementation of lung cancer screening

Adjuvant atezolizumab shows benefit in patients with stage II-IIIA non-small-cell lung cancer

Novel coronavirus identified from patients with pneumonia in Wuhan, China

Treatment of immune-mediated inflammatory diseases with tumor necrosis factor inhibitors is associated with lower COVID-19 hospitalization and death rates compared to other treatments

Working from home is the new normal as we combat the Covid-19

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early screening for emotional and cognitive issues may improve psychiatric outcomes for stroke patients
  • Artificial intelligence may assist in early detection of decreased ejection fraction on echocardiograms
  • #VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.